Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205150 · ClinicalTrials.gov registry record · Phase 2
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
A Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 15
- Study locations
NCT03205150: Completed Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH), sponsored by Novartis Pharmaceuticals.
NCT03205150 is a Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 107 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). The trial reports 15 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205150, a Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
Primary Outcome
Alanine aminotransferase (ALT) is an enzyme found primarily in the liver. ALT is increased with liver damage. In this study, the blood levels of ALT was used to detect liver injury. Baseline is defined as the mean of measurements taken at the Screening and Baseline visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LIK066
Study Locations (15)
Other
- Novartis Investigative Site - Buenos Aires
- Novartis Investigative Site - Haifa
- Novartis Investigative Site - Ramat Gan
- Novartis Investigative Site - Tel Aviv
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - Saint Petersburg
- Novartis Investigative Site - Chiayi City
- Novartis Investigative Site - Tainan
- Novartis Investigative Site - Bangkok
Louisiana
- Novartis Investigative Site - Baton Rouge
Missouri
- Novartis Investigative Site - St Louis
Tennessee
- Novartis Investigative Site - Knoxville
Texas
- Novartis Investigative Site - Live Oak
Buenos Aires
- Novartis Investigative Site - CABA
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2019-11-14 |
| Phase | Phase 2 |
What the finished NCT03205150 record still lists
NCT03205150 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Obese Patients With Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03205150 lists 15 locations in 7 states (Other, Louisiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT03205150 about?
NCT03205150 is a clinical study titled "Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients". The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
What is the current status of trial NCT03205150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-10-04. Estimated completion is 2019-11-14.
What conditions does trial NCT03205150 study?
This clinical trial studies the following conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT03205150?
The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT03205150?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03205150 being conducted?
This trial has 15 study locations across Louisiana, Missouri, Tennessee, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03205150's enrollment target sits among peer trials
107 646th of 2000 higher than 1,353 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI